阿托伐他汀对急性缺血性脑卒中患者血浆溶血磷脂酸的影响

目的：探讨阿托伐他汀对急性缺血性脑卒中患者血浆溶血磷脂酸（lysophosphatidi cacid，LPA）的干预作用。方法：110例脑梗塞患者，被随机分为阿托伐他汀组（57例）和常规治疗组（53例）。两组均给予钙拮抗剂、脑细胞活化剂、银杏达莫注射液及对症治疗。阿托伐他汀组加用阿托伐他汀20～40mg／d。两组病人人院后第二天清晨空腹静脉采血查血浆LPA和血脂水平，治疗14d后复查。结果：阿托伐他汀组和对照组治疗后LPA较治疗前均显著下降（P〈0．05～〈0．01）。且阿托伐他汀组下降更显著（2．53±0．75）μmol／L：（1．01±0．56）μmol／L.P〈0．01）。两组治疗前后总胆固醇（TC）与低密度脂蛋白一胆固醇（LDL-C）均有显著下降（P〈0．01，〈0．05）．但两组比较无显著性差异（P〉0．05）。结论：阿托伐他汀能显著降低急性脑梗塞患者血浆LPA水平，其作用与调脂作用似无明显相关。

Effects of atorvastatin on the plasma levels of lysophosphatidic acid in patients with acute cerebral infarction

Objective： To investigate the effects of atorvastatin on the plasma levels of lysophosphatidic acid in patients with acute cerebral infarction （ACI）. Methods： A total of 110 ACI patients were assigned randamly to routine therapy group and atorvastatin group （20-40mg/d, for 14 days above the base of routine therapy）. The plasma levels of LPA and blood lipid were determined before and 14 days after treatment. Results： The plasma levels of LPA decreased in both groups after treatment （P〈0. 05-〈0.01）, but that in atorvastatin group decreased more significantly （P〈 0.01）. The levels of blood lipid in both groups decreased significantly after treatment （P〈0. 05 -〈0. 01）, but no difference between two groups （P〈0. 05）. Conclusion： Atorvastatin can evidently decrease the plasma levels of LPA in patients with acute cerebral infarction, its effect doesn＇t depend on the influence of blood lipid.